Table 1.
Patient Characteristics at Baseline
| Characteristics | Total # Patients, N=54 |
|---|---|
| Age (y) | |
| Median | 62 |
| Range | 35–89 |
| Sex, n (%) | |
| Female | 29 (54) |
| Male | 25 (46) |
| ECOG performance status, n (%) | |
| 0 | 31 (57) |
| 1 | 23 (43) |
| Status of primary tumor, n (%) | |
| Resected, without residual disease | 12 (22) |
| Resected, with residual disease | 18 (33) |
| Unresected | 15 (28) |
| Recurrent | 5 (9) |
| Unknown | 4 (7) |
| Tumor grade, n (%) | |
| Grade I | 39 (72) |
| Grade II | 7 (13) |
| Grade III | 3 (6) |
| Grade IV | 3 (6) |
| Unknown | 2 (4) |
| Metastatic sites, n (%) | |
| Liver | 48 (89) |
| Lymph nodes | 34 (63) |
| Lung | 13 (24) |
| Bone | 12 (22) |
| Subcutaneous | 1 (2) |
| Brain | 1 (2) |
| Sum of target lesions in cm, median (range) | 12.5 (2.6–32.0) |
| Prior therapy, n (%) | |
| Systemic or regional therapy | 46 (85) |
| Surgery | 43 (80) |
| Radiation | 13 (24) |
| Progressive disease in preceding 7 months, n (%) | |
| Yes | 20 (37) |
| No | 2 (4) |
| Unknown | 32 (59) |
| Tumor Marker not detected | 21 (39%) |
| Tumor Marker detected | |
| 5-HIAA & Chromogranin A | 3 (6%) |
| 5-HIAA alone | 1 (2%) |
| Chromogranin A | 14 (26%) |
| Gastrin | 1 (2%) |
| Gastrin & Pancreastatin | 1 (2%) |
| Pancreastatin | 5 (9%) |
| Serotonin | 4 (7%) |
| Unknown/Missing | 4 (7%) |